Form 4: Inhibitor Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Francis E Odonnell Jr, Chief Executive Officer, a Director and 10% owner of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
Summary
- Grant/award: acquired 50,000 Common Stock on May 4, 2026; holds 150,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Francis E Odonnell Jr — Director, Officer (Chief Executive Officer), 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-05-04 | Grant/award | Common Stock | 50,000 | — | — | 150,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-05-04 | Grant/award (50,000 shares) |
Keywords
insider transaction, Form 4, INTI, Inhibitor Therapeutics, Inc., neutral, Francis E Odonnell Jr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.